


**Amendments to the Specification:**

Please amend the specification as follows:

Please replace paragraph [0010] starting on page 4 with the following amended paragraph:

[0010] TLK286, identified in the patent as TER 286 and named as  $\gamma$ -glutamyl- $\alpha$ -amino- $\beta$ -((2-ethyl-N,N,N,N-tetra(2'-chloro)ethylphosphoramidate)sulfonyl)propionyl-(R)-(-)-phenylglycine, is one of these compounds. TLK286 is the compound of the formula



and has the CAS name L- $\gamma$ -glutamyl-3-[[2-[[bis[bis(2-chloroethyl)amino]phosphinyl]oxy]ethyl]-sulfonyl]-L-alanyl-2-phenyl-(2R)-glycine. ~~TLK286 as the hydrochloride salt has the proposed United States Adopted Name of canglustratide hydrochloride. TLK286 as the hydrochloride salt has the United States Adopted Name of canfosfamide hydrochloride.~~ TLK286 is an anticancer compound that is activated by the actions of GST P1-1, and by GST A1-1, to release the cytotoxic phosphorodiamidate mustard moiety. Following activation of TLK286 by GST P1-1, apoptosis is induced through the stress response signaling pathway with the activation of MKK4, JNK, p38 MAP kinase, and caspase 3.